Stockscreener 앱 받기
0.569
7.48%
-0.046
전일 마감가:
$0.615
열려 있는:
$0.5966
하루 거래량:
192.88K
Relative Volume:
0.39
시가총액:
$18.89M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.174
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-9.02%
1개월 성능:
-9.68%
6개월 성능:
+49.74%
1년 성능:
-83.22%
1일 변동 폭
$0.5671
$0.61
1주일 범위
$0.5671
$0.6664
52주 변동 폭
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.641 | 862.34M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.57 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.61 | 121.44M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1521 | 322.13M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.82 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Advanced analytics toolkit walkthrough for Relmada Therapeutics Inc.Daily Pattern Analysis with Return Forecast - Newser
Is a relief rally coming for Relmada Therapeutics Inc. holdersIntraday Price Forecast Using Volume Models - Newser
What’s next for Relmada Therapeutics Inc. stock priceFree Early Entry Tips With Low Risk Zone - Newser
Published on: 2025-08-04 12:29:06 - metal.it
Will a bounce in Relmada Therapeutics Inc. offer an exitWeekly Setup Summary for Risk Controlled Trades - Newser
What are the latest earnings results for Relmada Therapeutics Inc.Get alerts on top growth stocks daily - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attentionFree Alert Feed for Momentum Based Picks - Newser
What makes Relmada Therapeutics Inc. stock price move sharplyMarket Downturn Defense Strategy Analysis - Newser
Using portfolio simulators with Relmada Therapeutics Inc. includedShort-Term Stock Trend Forecast Guide - Newser
What catalysts could drive Relmada Therapeutics Inc. stock higher in 2025Unlock powerful trading signals for profits - Jammu Links News
How volatile is Relmada Therapeutics Inc. stock compared to the marketRobust investment performance - Jammu Links News
How does Relmada Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for steady growth - Jammu Links News
What institutional investors are buying Relmada Therapeutics Inc. stockInvest in stocks with strong fundamentals - Jammu Links News
What analysts say about Relmada Therapeutics Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
What drives Relmada Therapeutics Inc. stock priceCapitalize on emerging market opportunities - Jammu Links News
Real time breakdown of Relmada Therapeutics Inc. stock performanceOversold Reversal Picks with Buy Zone - Newser
Using fundamentals and technicals on Relmada Therapeutics Inc.Capital Secure Pattern Signal Analysis Sheet - Newser
What is the risk reward ratio of investing in Relmada Therapeutics Inc. stockAccess daily stock market expert updates - Jammu Links News
What are analysts’ price targets for Relmada Therapeutics Inc. in the next 12 monthsUnbelievable profit margins - Jammu Links News
How strong is Relmada Therapeutics Inc. company’s balance sheetInvest in stocks with strong fundamentals - Jammu Links News
Why is Relmada Therapeutics Inc. stock attracting strong analyst attentionStay informed with daily expert analysis - Jammu Links News
What are Relmada Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Relmada Therapeutics (RLMD.US) will release its earnings reports after the market closes on August 7th. - 富途牛牛
How to monitor Relmada Therapeutics Inc. with trend dashboardsSmart Trade Mapping with Entry Details - Newser
Building trade automation scripts for Relmada Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Manila Times
Relmada Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Oncology and CNS Pipeline - Stock Titan
Relmada Therapeutics Inc. At Decision Level — Rebound or ResistanceReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 2.3% – Here’s What Happened - Defense World
Does Relmada Therapeutics Inc. stock perform well during market downturnsBeginner Investor Growth Plan For Every Investor - Jammu Links News
When is Relmada Therapeutics Inc. stock expected to show significant growthPost Market Outlook For Every Investor - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attention Monthly Trade Result and Signal Summary - Newser
Why Relmada Therapeutics Inc. stock attracts strong analyst attention AI Screener Based Stock Summary Report - metal.it
Is it the right time to buy Relmada Therapeutics Inc. stockPhenomenal returns - Jammu Links News
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 11 '24 |
Buy |
2.99 |
51,407 |
153,707 |
384,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
0.40%
0.08%
자본화:
|
볼륨(24시간):